Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation

Junichiro Sageshima, Gaetano Ciancio, Giselle Guerra, Jeffrey J. Gaynor, Deborah Cova, Alberto Zarak, Linda Chen, Adela Mattiazzi, Warren Kupin, David Roth, Lois Hanson, Alan S. Livingstone, Phillip Ruiz, George W. Burke

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Although antibody induction has gained in popularity, two agents are rarely combined. We retrospectively analyzed peripheral lymphocyte phenotypes of renal transplant recipients who received induction therapy with a different antibody/combination: alemtuzumab(C1H), Thymoglobulin(rATG), daclizumab(Dac), rATG. +. C1H, and rATG. +. Dac. CD4+ T-cells were suppressed by C1H and rATG. +. C1H, as well as by rATG and rATG. +. Dac but to a lesser extent. The effect lasted for 3. years at around 40% of baseline values. CD8+ T-cells showed a similar trend but had a more rapid recovery to baseline. CD19+ B-cells were effectively suppressed for 2. months by C1H and rATG. +. C1H, and abruptly returned to baseline afterwards; suppression by rATG(7 doses) was modest but lasted longer. A higher proportion of CD56. +. CD16+ Natural Killer cells in C1H treated patients suggested a relatively spared effect of C1H on this cell type. Low CD25+ T-cells by 5-dose Dac returned to baseline around 6. months, whereas rATG. +. C1H and rATG. +. Dac showed persistent effect. CD4. +. CD25hi T-cells were suppressed by both rATG. +. C1H and rATG. +. Dac, but the initial proportion of CD4. +. CD25hi T-cells among CD4+ T-cells and CD4. +. CD25hi/CD4. +. CD25lo ratio were significantly higher in rATG. +. C1H. Overall, with extensive and persistent lymphocyte suppression by a simple administration of agents, single-dose rATG. +. C1H induction can be an alternative in renal transplantation.

Original languageEnglish (US)
Pages (from-to)104-111
Number of pages8
JournalTransplant Immunology
Volume25
Issue number2-3
DOIs
StatePublished - Sep 1 2011
Externally publishedYes

Fingerprint

Lymphocyte Depletion
Antilymphocyte Serum
Kidney Transplantation
Rabbits
T-Lymphocytes
Lymphocytes
Antibodies
Natural Killer Cells
daclizumab
alemtuzumab
B-Lymphocytes
Phenotype
Kidney

Keywords

  • Alemtuzumab
  • Anti-thymocyte globulin
  • Induction therapy
  • Kidney transplantation
  • Monoclonal antibody

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Transplantation

Cite this

Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation. / Sageshima, Junichiro; Ciancio, Gaetano; Guerra, Giselle; Gaynor, Jeffrey J.; Cova, Deborah; Zarak, Alberto; Chen, Linda; Mattiazzi, Adela; Kupin, Warren; Roth, David; Hanson, Lois; Livingstone, Alan S.; Ruiz, Phillip; Burke, George W.

In: Transplant Immunology, Vol. 25, No. 2-3, 01.09.2011, p. 104-111.

Research output: Contribution to journalArticle

Sageshima, J, Ciancio, G, Guerra, G, Gaynor, JJ, Cova, D, Zarak, A, Chen, L, Mattiazzi, A, Kupin, W, Roth, D, Hanson, L, Livingstone, AS, Ruiz, P & Burke, GW 2011, 'Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation', Transplant Immunology, vol. 25, no. 2-3, pp. 104-111. https://doi.org/10.1016/j.trim.2011.07.002
Sageshima, Junichiro ; Ciancio, Gaetano ; Guerra, Giselle ; Gaynor, Jeffrey J. ; Cova, Deborah ; Zarak, Alberto ; Chen, Linda ; Mattiazzi, Adela ; Kupin, Warren ; Roth, David ; Hanson, Lois ; Livingstone, Alan S. ; Ruiz, Phillip ; Burke, George W. / Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation. In: Transplant Immunology. 2011 ; Vol. 25, No. 2-3. pp. 104-111.
@article{4676bb6404e642f8b5cf462b07ee2c3f,
title = "Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation",
abstract = "Although antibody induction has gained in popularity, two agents are rarely combined. We retrospectively analyzed peripheral lymphocyte phenotypes of renal transplant recipients who received induction therapy with a different antibody/combination: alemtuzumab(C1H), Thymoglobulin(rATG), daclizumab(Dac), rATG. +. C1H, and rATG. +. Dac. CD4+ T-cells were suppressed by C1H and rATG. +. C1H, as well as by rATG and rATG. +. Dac but to a lesser extent. The effect lasted for 3. years at around 40{\%} of baseline values. CD8+ T-cells showed a similar trend but had a more rapid recovery to baseline. CD19+ B-cells were effectively suppressed for 2. months by C1H and rATG. +. C1H, and abruptly returned to baseline afterwards; suppression by rATG(7 doses) was modest but lasted longer. A higher proportion of CD56. +. CD16+ Natural Killer cells in C1H treated patients suggested a relatively spared effect of C1H on this cell type. Low CD25+ T-cells by 5-dose Dac returned to baseline around 6. months, whereas rATG. +. C1H and rATG. +. Dac showed persistent effect. CD4. +. CD25hi T-cells were suppressed by both rATG. +. C1H and rATG. +. Dac, but the initial proportion of CD4. +. CD25hi T-cells among CD4+ T-cells and CD4. +. CD25hi/CD4. +. CD25lo ratio were significantly higher in rATG. +. C1H. Overall, with extensive and persistent lymphocyte suppression by a simple administration of agents, single-dose rATG. +. C1H induction can be an alternative in renal transplantation.",
keywords = "Alemtuzumab, Anti-thymocyte globulin, Induction therapy, Kidney transplantation, Monoclonal antibody",
author = "Junichiro Sageshima and Gaetano Ciancio and Giselle Guerra and Gaynor, {Jeffrey J.} and Deborah Cova and Alberto Zarak and Linda Chen and Adela Mattiazzi and Warren Kupin and David Roth and Lois Hanson and Livingstone, {Alan S.} and Phillip Ruiz and Burke, {George W.}",
year = "2011",
month = "9",
day = "1",
doi = "10.1016/j.trim.2011.07.002",
language = "English (US)",
volume = "25",
pages = "104--111",
journal = "Transplant Immunology",
issn = "0966-3274",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation

AU - Sageshima, Junichiro

AU - Ciancio, Gaetano

AU - Guerra, Giselle

AU - Gaynor, Jeffrey J.

AU - Cova, Deborah

AU - Zarak, Alberto

AU - Chen, Linda

AU - Mattiazzi, Adela

AU - Kupin, Warren

AU - Roth, David

AU - Hanson, Lois

AU - Livingstone, Alan S.

AU - Ruiz, Phillip

AU - Burke, George W.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Although antibody induction has gained in popularity, two agents are rarely combined. We retrospectively analyzed peripheral lymphocyte phenotypes of renal transplant recipients who received induction therapy with a different antibody/combination: alemtuzumab(C1H), Thymoglobulin(rATG), daclizumab(Dac), rATG. +. C1H, and rATG. +. Dac. CD4+ T-cells were suppressed by C1H and rATG. +. C1H, as well as by rATG and rATG. +. Dac but to a lesser extent. The effect lasted for 3. years at around 40% of baseline values. CD8+ T-cells showed a similar trend but had a more rapid recovery to baseline. CD19+ B-cells were effectively suppressed for 2. months by C1H and rATG. +. C1H, and abruptly returned to baseline afterwards; suppression by rATG(7 doses) was modest but lasted longer. A higher proportion of CD56. +. CD16+ Natural Killer cells in C1H treated patients suggested a relatively spared effect of C1H on this cell type. Low CD25+ T-cells by 5-dose Dac returned to baseline around 6. months, whereas rATG. +. C1H and rATG. +. Dac showed persistent effect. CD4. +. CD25hi T-cells were suppressed by both rATG. +. C1H and rATG. +. Dac, but the initial proportion of CD4. +. CD25hi T-cells among CD4+ T-cells and CD4. +. CD25hi/CD4. +. CD25lo ratio were significantly higher in rATG. +. C1H. Overall, with extensive and persistent lymphocyte suppression by a simple administration of agents, single-dose rATG. +. C1H induction can be an alternative in renal transplantation.

AB - Although antibody induction has gained in popularity, two agents are rarely combined. We retrospectively analyzed peripheral lymphocyte phenotypes of renal transplant recipients who received induction therapy with a different antibody/combination: alemtuzumab(C1H), Thymoglobulin(rATG), daclizumab(Dac), rATG. +. C1H, and rATG. +. Dac. CD4+ T-cells were suppressed by C1H and rATG. +. C1H, as well as by rATG and rATG. +. Dac but to a lesser extent. The effect lasted for 3. years at around 40% of baseline values. CD8+ T-cells showed a similar trend but had a more rapid recovery to baseline. CD19+ B-cells were effectively suppressed for 2. months by C1H and rATG. +. C1H, and abruptly returned to baseline afterwards; suppression by rATG(7 doses) was modest but lasted longer. A higher proportion of CD56. +. CD16+ Natural Killer cells in C1H treated patients suggested a relatively spared effect of C1H on this cell type. Low CD25+ T-cells by 5-dose Dac returned to baseline around 6. months, whereas rATG. +. C1H and rATG. +. Dac showed persistent effect. CD4. +. CD25hi T-cells were suppressed by both rATG. +. C1H and rATG. +. Dac, but the initial proportion of CD4. +. CD25hi T-cells among CD4+ T-cells and CD4. +. CD25hi/CD4. +. CD25lo ratio were significantly higher in rATG. +. C1H. Overall, with extensive and persistent lymphocyte suppression by a simple administration of agents, single-dose rATG. +. C1H induction can be an alternative in renal transplantation.

KW - Alemtuzumab

KW - Anti-thymocyte globulin

KW - Induction therapy

KW - Kidney transplantation

KW - Monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=80052338014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052338014&partnerID=8YFLogxK

U2 - 10.1016/j.trim.2011.07.002

DO - 10.1016/j.trim.2011.07.002

M3 - Article

C2 - 21784152

AN - SCOPUS:80052338014

VL - 25

SP - 104

EP - 111

JO - Transplant Immunology

JF - Transplant Immunology

SN - 0966-3274

IS - 2-3

ER -